Mesenchymal Stem Cell-Derived Exosomes in Cancer Resistance Against Therapeutics

被引:2
作者
Easwaran, Vignesh Balaji [1 ]
Pai, K. Maya S. [2 ]
Pai, K. Sreedhara Ranganath [1 ]
机构
[1] Manipal Acad Higher Educ, Manipal Coll Pharmaceut Sci, Dept Pharmacol, Manipal 576104, Karnataka, India
[2] Manipal Acad Higher Educ, Manipal Coll Pharmaceut Sci, Dept Pharm Practice, Manipal 576104, Karnataka, India
关键词
mesenchymal stem cells; exosomes; cancer; resistance; biomarkers; BREAST-CANCER; EXTRACELLULAR VESICLES; CHEMORESISTANCE; THERAPY; CXCR4;
D O I
10.3390/cancers17050831
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mesenchymal stem cells (MSCs) are specialized cells that can differentiate into various types of cells. MSCs can be utilized to treat cancer. However, a MSC is considered a double-edged sword, because it can promote tumor progression and support cancer cell growth. Likewise, MSC-derived exosomes (MSC-Exos) carry various intracellular materials and transfer them to other cells. MSC-Exos could also cause tumor progression, including brain cancer, breast cancer, hepatic cancer, lung cancer, and colorectal cancer, and develop resistance against therapies, mainly chemotherapy, radiotherapy, and immunotherapy. An MSC-Exo promotes tumor development and causes drug resistance in various cancer types. The mechanisms involved in cancer drug resistance vary depending on the cancer cell heterogeneity and complexity. In this article, we have explained the various biomarkers and mechanisms involved in the tumor and resistance development through MSC-Exos in different cancer types.
引用
收藏
页数:13
相关论文
共 75 条
[1]   Metabolomic Rewiring Promotes Endocrine Therapy Resistance in Breast Cancer [J].
Ahn, Songyeon ;
Park, Jun Hyoung ;
Grimm, Sandra L. ;
Piyarathna, Danthasinghe Waduge Badrajee ;
Samanta, Tagari ;
Putluri, Vasanta ;
Mezquita, Dereck ;
Fuqua, Suzanne A. W. ;
Putluri, Nagireddy ;
Coarfa, Cristian ;
Kaipparettu, Benny Abraham .
CANCER RESEARCH, 2024, 84 (02) :291-304
[2]   Overexpression of stromal cell-derived factor 1 and its receptor CXCR4 induces autocrine/paracrine cell proliferation in human pituitary adenomas [J].
Barbieri, Federica ;
Bajetto, Adriana ;
Stumm, Ralf ;
Pattarozzi, Alessandra ;
Porcile, Carola ;
Zona, Gianluigi ;
Dorcaratto, Alessandra ;
Ravetti, Jean-Louis ;
Minuto, Francesco ;
Spaziante, Renato ;
Schettini, Gennaro ;
Ferone, Diego ;
Florio, Tullio .
CLINICAL CANCER RESEARCH, 2008, 14 (16) :5022-5032
[3]   The action and resistance mechanisms of Lenvatinib in liver cancer [J].
Buttell, Anna ;
Qiu, Wei .
MOLECULAR CARCINOGENESIS, 2023, 62 (12) :1918-1934
[4]   Ezrin Inhibition Overcomes Acquired Resistance to Vemurafenib in BRAFV600E-Mutated Colon Cancer and Melanoma Cells In Vitro [J].
Car, Iris ;
Dittmann, Antje ;
Vasieva, Olga ;
Bockor, Luka ;
Grbcic, Petra ;
Pitesa, Nikolina ;
Klobucar, Marko ;
Pavelic, Sandra Kraljevic ;
Sedic, Mirela .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (16)
[5]   A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma [J].
Chen, Xiaoyue ;
Zhang, Minjie ;
Gan, Haiyun ;
Wang, Heping ;
Lee, Jeong-Heon ;
Fang, Dong ;
Kitange, Gaspar J. ;
He, Lihong ;
Hu, Zeng ;
Parney, Ian F. ;
Meyer, Fredric B. ;
Giannini, Caterina ;
Sarkaria, Jann N. ;
Zhang, Zhiguo .
NATURE COMMUNICATIONS, 2018, 9
[6]   Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer [J].
Chmielecki, Juliann ;
Gray, Jhanelle E. ;
Cheng, Ying ;
Ohe, Yuichiro ;
Imamura, Fumio ;
Cho, Byoung Chul ;
Lin, Meng-Chih ;
Majem, Margarita ;
Shah, Riyaz ;
Rukazenkov, Yuri ;
Todd, Alexander ;
Markovets, Aleksandra ;
Barrett, J. Carl ;
Hartmaier, Ryan J. ;
Ramalingam, Suresh S. .
NATURE COMMUNICATIONS, 2023, 14 (01)
[7]   Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer [J].
Clarke, Paul A. ;
Roe, Toby ;
Swabey, Kate ;
Hobbs, Steve M. ;
McAndrew, Craig ;
Tomlin, Kathy ;
Westwood, Isaac ;
Burke, Rosemary ;
van Montfort, Robert ;
Workman, Paul .
ONCOGENE, 2019, 38 (25) :5076-5090
[8]   Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer [J].
Cruz-Duarte, Raquel ;
de Almeida, Catia Rebelo ;
Negrao, Magda ;
Fernandes, Afonso ;
Borralho, Paula ;
Sobral, Daniel ;
Gallego-Paez, Lina M. ;
Machado, Daniel ;
Gramaca, Joao ;
Vilchez, Jose ;
Xavier, Ana T. ;
Ferreira, Miguel Godinho ;
Miranda, Ana R. ;
Mansinho, Helder ;
Brito, Maria J. ;
Pacheco, Teresa R. ;
Abreu, Catarina ;
Lucia-Costa, Ana ;
Mansinho, Andre ;
Fior, Rita ;
Costa, Luis ;
Martins, Marta .
CLINICAL CANCER RESEARCH, 2022, 28 (06) :1203-1216
[9]   The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies [J].
Ferro, Alessandra ;
Marinato, Gian Marco ;
Mulargiu, Cristiana ;
Marino, Monica ;
Pasello, Giulia ;
Guarneri, Valentina ;
Bonanno, Laura .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 196
[10]   A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAFV600 wild-type colorectal cancer [J].
Georgiou, Alexandros ;
Stewart, Adam ;
Vlachogiannis, Georgios ;
Pickard, Lisa ;
Valeri, Nicola ;
Cunningham, David ;
Whittaker, Steven R. ;
Banerji, Udai .
CELLULAR ONCOLOGY, 2021, 44 (05) :1197-1206